Vital research into children’s cancer has been bolstered through generous donations at the 2020 Tour de Cure Spring Lunch, with more than $1 million raised.
Sponsored by presenting partner The iQ Group Global, the annual event received a raft of donations and support, with performances by Delta Goodrem, Matthew Copley and Prinnie Stevens.
Channel Seven’s David Koch, Mark Beretta, James Tobin and Larry Edmur and The Project’s Alicia Lagourcette were also in attendance.
Funds raised from this year’s event will support a plethora of cancer research, including acute lymphoblastic leukaemia (ALL); the most common and aggressive childhood cancer in Australia.
The donations will also fund minimal residual disease testing (MRD) which can determine whether cancer cells in an acute lymphoblastic leukaemia patient’s body have survived cancer treatment.
The $2,700 per-patient tests can also identify unique genetic markers for each patient, predict relapses and double the rate of survival for children.
Tour de Cure Chairman, Bruno Maurel said 2020 had been a tumultuous year for cancer research and was grateful for the overwhelming support at last month’s event.
“In 2020 the world has faced a new enemy, which both claimed lives and crippled the economy,” Mr Maurel said.
“This has severely impacted the cancer world, in that the virus has made the cancer journey even harder for patients.
“We also know that testing is down between 30-50 per cent and this will have a major impact in the future, as we know that early detection significantly impacts the chances of survival.
“Tour de Cure is committed to supporting cancer research in Australia.”
Dr Michelle Henderson, who leads MRD testing at the Children’s Cancer Institute of Australia, said it was paramount research into children’s cancer continue unabated despite the global impacts of the COVID-19 pandemic.
“Over a thousand children each year are being diagnosed with cancer. About a fifth of those children won’t survive their cancer,” Dr Henderson said.
“We know that that’s not good enough and our vision is to cure every child of their cancer.”
The iQ Group Global founder and Group Chief Executive Officer Dr George Syrmalis said supporting cancer research is essential to the development of novel treatment options to improve the quality of life of patients, in Australia and globally.
“At The iQ Group global, our mission is to create the medicines of tomorrow.
“We know that Acute Lymphoblastic Leukaemia is the most common childhood cancer in Australia and we are very proud to support Tour de Cure in their work to address this urgent unmet clinical need for hundreds of families across the country.”
About The iQ Group Global
The iQ Group Global is a consortium of companies that find, fund and develop bioscience discoveries to create life-changing medical innovations. The Group provides a turnkey solution for bioscience companies, spanning corporate advisory and investment banking, through to research, development, and commercialization of life science assets. www.theiqgroupglobal.com
About Tour de Cure
Tour de Cure hosts gala events and organises cycling and walking tours across Australia and also delivers programs promoting cancer prevention to Australian schools. Since 2007, Tour de Cure has raised more than $60 million and funded 502 cancer projects, scientists and researchers resulting in 40 significant cancer breakthroughs in research and care.